MindRank Announces First Patient Dosed in Phase IIb Trial of Oral Small Molecule GLP-1RA MDR-001
MindRank
AI Drug Developer
October 10, 2024 - Focused on using AI-driven new drug research and development"MindRank"Announced that its self-developed AI-assisted designMindRank's Small Molecule Oral GLP-1RA New Drug MDR-001 Completes First Dose Group Administration in Phase IIb Clinical Trial.
This randomized, double-blind, placebo-controlled multicenter Phase IIb clinical study aims to further evaluate the efficacy and safety of long-term administration of the oral small molecule MDR-001 tablets in overweight or obese subjects, providing a basis for dose selection in the subsequent Phase III clinical trial. The study is led by Professor Linnong Ji from Peking University People's Hospital and jointly conducted by nineteen centers across China, with a planned enrollment of 300 adult overweight or obese subjects.
MDR-001 completed the Phase I clinical single-dose escalation trial in the first half of 2023 and initiated the Phase Ib/IIa dose-finding study in September 2023. To date, the Phase Ib/IIa trial has been fully completed, and the results show:After 12 weeks of taking MDR-001, the subjects' average weight decreased by 9.0% (placebo 2.1%), with an average decrease of 6.9% after placebo deduction. Among them, 87% of the subjects lost more than 5% of their body weight. Meanwhile, MDR-001 demonstrated good safety and tolerability, with no serious adverse events occurring, and no subjects withdrew due to adverse events. The maximum tolerated dose acceptable to patients was far from being reached.The most commonly reported adverse events during the treatment period were mild to moderate gastrointestinal adverse events.
The launch of this multi-center Phase IIb clinical trial marks the official entry of the MDR-001 project into the registrational clinical research stage, which will accelerate the provision of better treatment options for patients in China and internationally.
About MDR-001
MDR-001 is a product developed by MindRank using its self-developed Molecule Pro.™Innovative drug pipeline designed with the assistance of a one-stop AI drug discovery platform. Clinical research results show that MDR-001 has good safety and pharmacokinetic characteristics, with a clear linear relationship observed across different dose groups, and its preclinical advantages have been successfully translated into clinical outcomes.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company’s vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby helping more lives regain health.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018-2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Companies list as one of "China's most socially influential startups."
Related Reading:
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Cooperation: bd@mindrank.ai
Other: info@mindrank.ai